NVIDIA Forecast, price target & analysts
NVIDIA Target price 2026 - Analyst rating & recommendation
NVIDIA Classifications & Recommendation
NVIDIA Price Target
| Target Price | $321.30 |
| Price | $221.30 |
| Potential | 45.19% |
| Number of Estimates | 62 |
| 62 Analysts have issued a price target NVIDIA 2027 . The average NVIDIA target price is $321.30. This is 45.19% higher than the current stock price. The highest price target is $540.75 144.35% , the lowest is $181.80 17.85% . | |
| A rating was issued by 69 analysts: 65 Analysts recommend NVIDIA to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the NVIDIA stock has an average upside potential 2027 of 45.19% . Most analysts recommend the NVIDIA stock at Purchase. |
Sales and Margin forecast 2027, 2028 to 2034
67 Analysts have issued a sales forecast NVIDIA 2027 . The average NVIDIA sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
36 Analysts have issued an NVIDIA EBITDA forecast 2027. The average NVIDIA EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
68 NVIDIA Analysts have issued a net profit forecast 2027. The average NVIDIA net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2034
Current NVIDIA Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Oct 01 2026 |
| Rosenblatt |
Buy
➜
Buy
|
Unchanged | Sep 29 2026 |
| Piper Sandler |
➜
Overweight
|
Initiated | Sep 10 2026 |
| Needham |
Buy
➜
Buy
|
Unchanged | Sep 04 2026 |
| Rosenblatt |
Buy
➜
Buy
|
Unchanged | Sep 04 2026 |
| Bernstein |
Outperform
➜
Outperform
|
Unchanged | Aug 27 2026 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Aug 27 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Oct 01 2026 |
|
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Sep 29 2026 |
|
Initiated
Piper Sandler:
➜
Overweight
|
Sep 10 2026 |
|
Unchanged
Needham:
Buy
➜
Buy
|
Sep 04 2026 |
|
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Sep 04 2026 |
|
Unchanged
Bernstein:
Outperform
➜
Outperform
|
Aug 27 2026 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Aug 27 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
